Tarsus Pharmaceuticals price target raised to $88 from $72 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $88 from $72 and keeps a Neutral rating on the shares. The firm upped its sales estimates for Xdemvy ahead of the Q3 results based on its conviction in the launch trajectory.